Omeprazole
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedAbout Omeprazole
Omeprazole is a phase 3 stage product being developed by AstraZeneca for GERD. The current trial status is completed. This product is registered under clinical trial identifier NCT00256737. Target conditions include GERD.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01921920 | Phase 1 | Completed |
| NCT00259051 | Phase 3 | Completed |
| NCT00259077 | Phase 3 | Completed |
| NCT00641264 | Approved | Completed |
| NCT00256737 | Phase 3 | Completed |
Competing Products
20 competing products in GERD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rabeprazole ER + Ranitidine | Eisai | Phase 3 | 77 |
| Rabeprazole sodium | Eisai | Phase 1 | 33 |
| Rabeprazole sodium + Esomeprazole | Eisai | Phase 3 | 77 |
| rabeprazole sodium + Placebo | Eisai | Phase 3 | 77 |
| Rabeprazole ER + Ranitidine | Eisai | Phase 3 | 77 |
| Rabeprazole sodium 5 mg + Rabeprazole sodium 10 mg | Eisai | Phase 1 | 33 |
| rabeprazole + rabeprazole | Eisai | Phase 3 | 77 |
| Rabeprazole sodium + Esomeprazole | Eisai | Phase 3 | 77 |
| Rabeprazole sodium + Esomeprazole | Eisai | Phase 3 | 77 |
| ONO-8539 | Ono Pharmaceutical | Phase 1 | 33 |
| esomeprazole 40 mg | Johnson & Johnson | Pre-clinical | 23 |
| esomeprazole (Nexium®) + Xolaam® | AstraZeneca | Approved | 85 |
| esomeprazole | AstraZeneca | Pre-clinical | 23 |
| Esomeprazole | AstraZeneca | Approved | 85 |
| Esomeprazole | AstraZeneca | Approved | 85 |
| esomeprazole magnesium | AstraZeneca | Phase 1 | 33 |
| Esomeprazole | AstraZeneca | Approved | 85 |
| Esomeprazole | AstraZeneca | Phase 3 | 77 |
| Esomeprazole (Nexium) | AstraZeneca | Approved | 85 |
| Open Label Run In Esomeprazole + Double Blind Esomeprazole + Double Blind Placebo | AstraZeneca | Phase 3 | 77 |